ALGS on Nasdaq
Aligos Therapeutics, Inc.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Humacyte, Inc., Proteon Therapeutics or DYADIC INTERNATIONAL INC, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$69.5M
- Income tax0¢$314.0K
Out of $2.2M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue from collaborations | $0 | $334.0K |
| Revenue from customers | $2.2M | $3.6M |
| Research and development | $69.5M | $70.3M |
| General and administrative | $20.7M | $22.8M |
| Total operating expenses | $90.2M | $93.1M |
| Loss from operations | -$88.0M | -$89.2M |
| Interest and other income, net | $3.9M | $4.4M |
| Change in fair value of 2023 Common Warrants | $60.2M | -$46.1M |
| Loss before income tax | -$23.9M | -$130.9M |
| Income tax provision | -$314.0K | -$331.0K |
| Net loss | -$24.2M | -$131.2M |
| Unrealized gain on available-for-sale securities | $22.0K | $9.0K |
| Unrealized loss on pension plans | -$5.0K | -$103.0K |
| Other comprehensive income (loss) | $17.0K | -$94.0K |
| Comprehensive loss | -$24.2M | -$131.3M |
| Net loss per share, basic | -$2.45 | -$20.94 |
| Net loss per share, diluted | -$2.45 | -$20.94 |
| Weighted average shares of common stock, basic | 9.9M shares | 6.3M shares |
| Weighted average shares of common stock, diluted | 9.9M shares | 6.3M shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2024-08-31 |
|---|---|---|---|
| Cash and cash equivalents | $18.3M | $37.0M | |
| Restricted cash | $110.0K | $110.0K | |
| Short-term investments | $59.5M | $19.9M | |
| Other current assets | $4.9M | $5.1M | |
| Total current assets | $82.9M | $62.1M | |
| Operating lease right-of-use assets | $3.1M | $5.0M | |
| Property and equipment, net | $1.9M | $2.4M | |
| Other assets | $715.0K | $627.0K | |
| Total assets | $88.5M | $70.1M | |
| Accounts payable | $4.0M | $2.6M | |
| Accrued liabilities | $13.5M | $15.6M | |
| Operating lease liabilities, current | $3.6M | $3.4M | |
| Finance lease liabilities, current | $145.0K | $36.0K | |
| Deferred revenue, current | $0 | $151.0K | |
| Total current liabilities | $21.2M | $21.7M | |
| Operating lease liabilities, net of current portion | $1.5M | $4.8M | |
| Finance lease liabilities, net of current portion | $0 | $122.0K | |
| 2023 Common Warrants liability | $12.2M | $72.4M | |
| Long term liability | $47.0K | $46.0K | |
| Total liabilities | $35.0M | $99.1M | |
| Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | $0 | $0 | |
| Common stock, $0.0001 par value; 115,800,000 shares and 20,800,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 6,178,230 and 3,864,436 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $9.0K | $8.0K | |
| Additional paid-in capital | $695.3M | $588.6M | |
| Accumulated deficit | -$642.2M | -$618.0M | |
| Accumulated other comprehensive income | $468.0K | $451.0K | |
| Total stockholders' equity (deficit) | $53.5M | -$29.0M | |
| Total liabilities and stockholders' equity (deficit) | $88.5M | $70.1M | |
| Preferred Stock, Par Value | $0.00 | $0.00 | |
| Preferred Stock, Shares Authorized | 10.0M shares | 10.0M shares | |
| Preferred Stock, Shares Issued | 0 shares | 0 shares | |
| Preferred Stock, Shares Outstanding | 0 shares | 0 shares | |
| Common Stock, Par Value | $0.00 | $0.00 | |
| Common Stock, Shares Authorized | 115.8M shares | 20.8M shares | |
| Common Stock, Shares, Issued | 6.2M shares | 3.9M shares | |
| Common Stock, Shares, Outstanding | 6.2M shares | 3.9M shares | 79.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$24.2M | -$131.2M |
| Accretion of discount on investments | -$2.2M | -$1.8M |
| Non cash lease expense | $1.9M | $1.6M |
| Change in fair value of 2023 Common Warrants | -$60.2M | $46.1M |
| Depreciation expense | $930.0K | $1.0M |
| Stock-based compensation including ESPP | $5.0M | $8.5M |
| Accounts payable | $1.4M | $54.0K |
| Accrued liabilities | -$2.0M | -$1.4M |
| Operating lease liabilities | -$3.1M | -$2.7M |
| Deferred revenue | -$151.0K | -$1.2M |
| Other assets | $96.0K | $216.0K |
| Net cash and cash equivalents used in operating activities | -$82.5M | -$80.7M |
| Maturities of short-term investments | $127.5M | $90.0M |
| Purchase of short-term investments | -$164.9M | -$108.1M |
| Purchases of property and equipment | -$437.0K | -$130.0K |
| Net cash and cash equivalents used in investing activities | -$37.8M | -$18.3M |
| Proceeds from issuance of common stock upon exercise of pre-funded warrants | $2.0K | |
| Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with PIPE offering, net of costs | $101.3M | |
| Payments on finance lease | -$14.0K | -$83.0K |
| Proceeds from the ESPP purchase | $304.0K | $436.0K |
| Net cash and cash equivalents provided by financing activities | $101.6M | $355.0K |
| Net decrease in cash, cash equivalents, and restricted cash | -$18.7M | -$98.7M |
Timeline
- Feb 11, 2025Funding Raised $105 million in a private offering of equity13
Recent filings
- Sep 15, 20268-K
- Aug 6, 20268-K
- Aug 6, 202610-Q
- Aug 6, 2026S-8
- Jun 29, 20264
- Jun 29, 20264
- Jun 29, 20264
- Jun 29, 20264
- Jun 29, 20264
- Jun 29, 20264
- Jun 26, 20268-K
- Jun 24, 2026SCHEDULE 13D
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G
- May 7, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13